Nerve growth factor (NGF) and its precursor (proNGF) are primarily considered as
regulators of neuronal function that induce their responses via the tyrosine kinase
receptor TrkA and the pan-neurotrophin receptor p75NTR. It has been generally held that
NGF exerts its effects primarily through TrkA, inducing a cascade of tyrosine
kinase-initiated responses, while proNGF binds more strongly to p75NTR. When this latter
entity interacts with a third receptor, sortilin, apoptotic responses are induced in
contrast to the survival/differentiation associated with the other two. Recent studies
have outlined portions of the downstream phosphoproteome of TrkA in the neuronal PC12
cells and have clarified the contribution of individual docking sites in the TrkA
endodomain. The patterns observed showed a similarity with the profile induced by the
epidermal growth factor receptor, which is extensively associated with oncogenesis.
Indeed, as with other neurotrophic factors, the distribution of TrkA and p75NTR is not
limited to neuronal tissue, thus providing an array of targets outside the nervous
systems. One such source is breast cancer cells, in which NGF and proNGF stimulate breast
cancer cell survival/growth and enhance cell invasion, respectively. This latter activity
is exerted via TrkA (as opposed to p75NTR) in conjunction with sortilin. Another tissue
overexpressing proNGF is prostate cancer and here the ability of cancer cells to induce
neuritogenesis has been implicated in cancer progression. These studies show that the
non-neuronal functions of proNGF/NGF are likely integrated with their neuronal activities
and point to the clinical utility of these growth factors and their receptors as
biomarkers and therapeutic targets for metastasis and cancer pain.